GGT1 and prostate carcinoma: Two studies reported the use of prostate-specific antigen (PSA) and gamma-glutamyltransferase 1 (GGT1) to distinguish between normal or benign prostatic hyperplasia and prostate cancer patients, as the PSA and GGT1 protein levels were markedly higher in exosomes isolated from the blood of prostate cancer patients [38,39].